The small-molecule protein synthesis inhibitor CRS3121 met its primary endpoints, with high rates of clinical cure at day 12 and low rates of CDI recurrence.
The vaccine didn't reduce C difficile infections in at-risk adults, but it did show the potential to reduce infection severity and limit need for medical attention.
The analysis suggests administration of Rebyota is associated with significant restoration of microbiota and bile acid composition.
Researchers say the findings suggest oversight of C diff patients by infectious disease specialists may result in better outcomes and resource management.
The treatment remained protective against recurrent C difficile infection in 86% of patients over a span of 2 years despite antibiotic exposure.
A longitudinal household study found shared C difficile strains in 17 of 28 families, with the infant detected first in most instances.
The CDC-developed strategy did not reduce incidence of hospital-onset C difficile over time at participating hospitals, but implementation was affected by COVID-19.
The American Gastroenterological Association says the document is the first comprehensive, evidence-based guideline on the use of FMT for recurrent C difficile.
Treatment with the narrow-spectrum investigational antibiotic ridinilazole resulted in a 53% relative reduction of recurrent C difficile infection compared with vancomycin.
In a population-based study, patients recently exposed to antibiotics and proton pump inhibitors had an 18-fold increase in the risk of C diff infection.
